OTCPK:SHTD.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. More Details


Snowflake Analysis

Established dividend payer and fair value.


Similar Companies

Share Price & News

How has Sinopharm Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SHTD.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.1%

SHTD.F

-1.5%

US Healthcare

-3.1%

US Market


1 Year Return

-31.1%

SHTD.F

16.7%

US Healthcare

12.7%

US Market

Return vs Industry: SHTD.F underperformed the US Healthcare industry which returned 16.7% over the past year.

Return vs Market: SHTD.F underperformed the US Market which returned 12.7% over the past year.


Shareholder returns

SHTD.FIndustryMarket
7 Day-2.1%-1.5%-3.1%
30 Day-8.0%-5.4%-2.9%
90 Day-9.4%1.5%8.2%
1 Year-31.1%-31.1%18.3%16.7%15.3%12.7%
3 Year-48.0%-48.0%26.0%20.5%37.8%28.5%
5 Year-37.3%-37.3%55.9%44.9%90.9%69.4%

Price Volatility Vs. Market

How volatile is Sinopharm Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?

7.62x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SHTD.F ($2.3) is trading above our estimate of fair value ($1.84)

Significantly Below Fair Value: SHTD.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SHTD.F is good value based on its PE Ratio (7.6x) compared to the US Healthcare industry average (21.9x).

PE vs Market: SHTD.F is good value based on its PE Ratio (7.6x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: SHTD.F is poor value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: SHTD.F is good value based on its PB Ratio (0.9x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

7.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SHTD.F's forecast earnings growth (7.3% per year) is above the savings rate (2.2%).

Earnings vs Market: SHTD.F's earnings (7.3% per year) are forecast to grow slower than the US market (23.1% per year).

High Growth Earnings: SHTD.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: SHTD.F's revenue (9.6% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: SHTD.F's revenue (9.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SHTD.F's Return on Equity is forecast to be low in 3 years time (13.4%).


Next Steps

Past Performance

How has Sinopharm Group performed over the past 5 years?

11.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SHTD.F has high quality earnings.

Growing Profit Margin: SHTD.F's current net profit margins (1.4%) are lower than last year (1.6%).


Past Earnings Growth Analysis

Earnings Trend: SHTD.F's earnings have grown by 11.9% per year over the past 5 years.

Accelerating Growth: SHTD.F's earnings growth over the past year (2.6%) is below its 5-year average (11.9% per year).

Earnings vs Industry: SHTD.F earnings growth over the past year (2.6%) underperformed the Healthcare industry 31.1%.


Return on Equity

High ROE: SHTD.F's Return on Equity (12.6%) is considered low.


Next Steps

Financial Health

How is Sinopharm Group's financial position?


Financial Position Analysis

Short Term Liabilities: SHTD.F's short term assets (CN¥264.9B) exceed its short term liabilities (CN¥208.7B).

Long Term Liabilities: SHTD.F's short term assets (CN¥264.9B) exceed its long term liabilities (CN¥15.0B).


Debt to Equity History and Analysis

Debt Level: SHTD.F's debt to equity ratio (101.3%) is considered high.

Reducing Debt: SHTD.F's debt to equity ratio has increased from 83.2% to 101.3% over the past 5 years.

Debt Coverage: SHTD.F's debt is not well covered by operating cash flow (5.4%).

Interest Coverage: SHTD.F's interest payments on its debt are well covered by EBIT (6.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Sinopharm Group current dividend yield, its reliability and sustainability?

3.87%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: SHTD.F's dividend (3.87%) is higher than the bottom 25% of dividend payers in the US market (1.71%).

High Dividend: SHTD.F's dividend (3.87%) is low compared to the top 25% of dividend payers in the US market (4.88%).


Stability and Growth of Payments

Stable Dividend: SHTD.F's dividends per share have been stable in the past 10 years.

Growing Dividend: SHTD.F's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.5%), SHTD.F's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: SHTD.F's dividends in 3 years are forecast to be well covered by earnings (31.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Yong Liu (51 yo)

2.83yrs

Tenure

CN¥7,447,000

Compensation

Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm ...


CEO Compensation Analysis

Compensation vs Market: Yong's total compensation ($USD1.09M) is below average for companies of similar size in the US market ($USD7.46M).

Compensation vs Earnings: Yong's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Zhiming Li
Executive Chairman3.5yrsCN¥13.35m0.0027%
CN¥ 195.1k
Yong Liu
President & Executive Director2.83yrsCN¥7.45m0.0022%
CN¥ 157.5k
Qingming Yu
Executive Director2.25yrsCN¥3.47m0.0032%
CN¥ 227.7k
Xiuchang Jiang
CFO & Vice President10.33yrsno datano data
Wei Liu
Joint Company Secretary9.08yrsno datano data
Yijian Wu
Joint Company Secretary1.75yrsno datano data
Wanyong Lian
Vice Presidentno datano datano data
Shuangjun Xu
Non-Executive Vice President9.5yrsno datano data
Wanjun Ma
Vice President10yrsno datano data
Dongjiu Li
Vice President2.67yrsno datano data
Maisong Cai
Vice President2.67yrsno datano data

6.0yrs

Average Tenure

51yo

Average Age

Experienced Management: SHTD.F's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Zhiming Li
Executive Chairman3.5yrsCN¥13.35m0.0027%
CN¥ 195.1k
Yong Liu
President & Executive Director2.83yrsCN¥7.45m0.0022%
CN¥ 157.5k
Qingming Yu
Executive Director2.25yrsCN¥3.47m0.0032%
CN¥ 227.7k
Ping Ma
Non-Executive Director3.92yrsno datano data
Qiyu Chen
Non-Executive Vice Chairman6.83yrsno datano data
Fumin Zhuo
Independent Non-Executive Director4.5yrsCN¥300.00kno data
Jindong Deng
Non-Executive Director13.08yrsno datano data
Tak Lung Wu
Independent Non-Executive Directorno datano datano data
Peiyu Li
Independent Non-Executive Directorno datano datano data
Deyong Wen
Non-Executive Director3yrsno datano data
Weifeng Yu
Independent Non-Executive Directorno datano datano data
Yifang Wu
Chief Supervisorno datano datano data

3.7yrs

Average Tenure

55.5yo

Average Age

Experienced Board: SHTD.F's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SHTD.F insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.


Top Shareholders

Company Information

Sinopharm Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sinopharm Group Co., Ltd.
  • Ticker: SHTD.F
  • Exchange: OTCPK
  • Founded: 2003
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: HK$54.977b
  • Listing Market Cap: HK$7.094b
  • Shares outstanding: 3.12b
  • Website: https://www.sinopharmgroup.com.cn

Number of Employees


Location

  • Sinopharm Group Co., Ltd.
  • Sinopharm Plaza
  • No. 1001 Zhongshan Road (West)
  • Shanghai
  • Shanghai Province
  • 200051
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1099SEHK (The Stock Exchange of Hong Kong Ltd.)YesForeign Shares-Foreign ListedHKHKDSep 2009
SHTD.FOTCPK (Pink Sheets LLC)YesForeign Shares-Foreign ListedUSUSDSep 2009
X2SDB (Deutsche Boerse AG)YesForeign Shares-Foreign ListedDEEURSep 2009
1099SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)YesForeign Shares-Foreign ListedHKHKDSep 2009
1099SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)YesForeign Shares-Foreign ListedHKHKDSep 2009
SHTD.YOTCPK (Pink Sheets LLC)ADRUSUSDAug 2012

Biography

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. Its Pharmaceutical Distribution se ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 05:39
End of Day Share Price2020/09/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.